GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults
The National Health Care Institute has assessed whether the hepatitis B vaccine PreHevbri® can be included in the Medicine Reimbursement System (GVS). This medicinal product is used as active immunisation against hepatitis B for high-risk groups. The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to include PreHevbri® in List 1A and List 2 of the reimbursement conditions.
Download "GVS advice hepatitis B vaccine (PreHevbri®) for active immunisation against hepatitis B in adults"
Indication for which reimbursement is requested
PreHevbri® is indicated for active immunisation against infections caused by all known subtypes of the hepatitis B virus in adults.
Recommendations from the National Health Care Institute
The National Health Care Institute concludes that PreHevbri® is interchangeable with 2 other hepatitis B vaccines included in the GVS, namely Engerix-B® and HBVAXPRO 10®. Therefore, the National Health Care Institute advises the Minister of VWS to include the hepatitis B vaccine PreHevbri® on List 1A, in cluster 0J07BCAP V. We also recommend that the existing List 2 reimbursement conditions applicable to hepatitis vaccines should also apply to PreHevbri®.
Medicine Reimbursement System (GVS)
PreHevbri® is an outpatient medicinal product. Outpatient medicinal products are medicinal products for home use available at the pharmacy on prescription from a physician. They are only reimbursed from the basic health care package if they are listed in the GVS. The amount of the reimbursement depends on the list the product is included. Interchangeable medicinal products are clustered in List 1A. These may be subject to a reimbursement limit. Unique medicinal products are listed in List 1B. There is no reimbursement limit for these products. Additional conditions may apply for reimbursement. In that case, a medicinal product is also listed in List 2.
The National Health Care Institute sends an advisory report to the Minister of VWS. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic health care package.